PTPRC and neoplasm: These findings validate that repeated CD45+ depletions enrich tumor cells that are representative of the original tumor cell population and can increase tumor cell percentage to ~ 50% or more, thereby allowing drug sensitivity evaluation to be performed on a majority of tumor cells.